• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Differences in Early Immunosuppressive Therapy Among Liver Retransplantation Recipients in a National Cohort.在全国队列中,肝移植受者早期免疫抑制治疗的差异。
Transplantation. 2021 Aug 1;105(8):1800-1807. doi: 10.1097/TP.0000000000003417.
2
Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.丙型肝炎复发肝再次移植生存的预测因素及评分应用
World J Gastroenterol. 2016 May 14;22(18):4547-58. doi: 10.3748/wjg.v22.i18.4547.
3
The Evolution of Redo Liver Transplantation Over 35 Years: Analysis of 654 Consecutive Adult Liver Retransplants at a Single Center.35 年来肝移植再手术的演变:单中心 654 例成人肝再移植的分析。
Ann Surg. 2023 Sep 1;278(3):441-451. doi: 10.1097/SLA.0000000000005962. Epub 2023 Jun 26.
4
Early Vs Late Liver Retransplantation: Different Characteristics and Prognostic Factors.早期与晚期肝脏再次移植:不同特征及预后因素
Transplant Proc. 2018 Nov;50(9):2668-2674. doi: 10.1016/j.transproceed.2018.03.040. Epub 2018 Mar 16.
5
Liver Retransplantation Associated With Kidney Transplantation for End-stage Liver Graft Disease and Renal Insufficiency: A Morbid Procedure on a Unique Subgroup of Patients.肝移植联合肾移植治疗终末期肝移植供体疾病和肾功能不全:一种针对独特亚组患者的高风险手术。
Transplantation. 2020 Jul;104(7):1403-1412. doi: 10.1097/TP.0000000000003035.
6
Comparison of short- and long-term outcomes after early versus late liver retransplantation: a single-center experience.早期与晚期肝移植后短期和长期结局比较:单中心经验。
J Surg Res. 2013 Dec;185(2):877-82. doi: 10.1016/j.jss.2013.07.013. Epub 2013 Jul 31.
7
Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index.美国再次肝移植的生存获益:基于丙型肝炎状态和供体风险指数的连续终末期肝病模型分析
Am J Transplant. 2014 Nov;14(11):2588-94. doi: 10.1111/ajt.12867. Epub 2014 Sep 19.
8
The Liver Retransplantation Risk Score: a prognostic model for survival after adult liver retransplantation.肝移植后再移植风险评分:成人肝移植后生存的预后模型。
Transpl Int. 2021 Oct;34(10):1928-1937. doi: 10.1111/tri.13956. Epub 2021 Jul 16.
9
Modern Outcomes After Liver Retransplantation: A Single-center Experience.肝移植后现代结局:单中心经验。
Transplantation. 2023 Jul 1;107(7):1513-1523. doi: 10.1097/TP.0000000000004500. Epub 2023 Jun 20.
10
Predictive index for long-term survival after retransplantation of the liver in adult recipients: analysis of a 26-year experience in a single center.成人肝移植后长期生存的预测指标:单中心 26 年经验分析。
Ann Surg. 2011 Sep;254(3):444-8; discussion 448-9. doi: 10.1097/SLA.0b013e31822c5878.

引用本文的文献

1
Indications and Outcomes with Liver Retransplantation in 2025.2025年肝脏再次移植的适应症与结果
Dig Dis Sci. 2025 Jan;70(1):29-38. doi: 10.1007/s10620-024-08741-x. Epub 2024 Nov 22.
2
Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries.移植后机会性感染住院及相关危险因素:医疗保险受益人的全国队列研究。
Transpl Infect Dis. 2024 Aug;26(4):e14317. doi: 10.1111/tid.14317. Epub 2024 Jun 9.
3
Graft-recipient-weight ratio and lowered immunosuppression is important for the success of adult liver retransplantation.供体-受者体重比和降低免疫抑制对于成人肝移植再移植的成功非常重要。
Sci Rep. 2023 Aug 7;13(1):12778. doi: 10.1038/s41598-023-39007-7.
4
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.诱导免疫抑制不会加重肝癌肝移植后肿瘤复发。
Transplantation. 2023 Jul 1;107(7):1524-1534. doi: 10.1097/TP.0000000000004487. Epub 2023 Jan 25.

在全国队列中,肝移植受者早期免疫抑制治疗的差异。

Differences in Early Immunosuppressive Therapy Among Liver Retransplantation Recipients in a National Cohort.

机构信息

Department of Medicine, University of Pennsylvania, Philadelphia, PA.

Division of Transplant Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA.

出版信息

Transplantation. 2021 Aug 1;105(8):1800-1807. doi: 10.1097/TP.0000000000003417.

DOI:10.1097/TP.0000000000003417
PMID:32804798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7881052/
Abstract

BACKGROUND

There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT).

METHODS

This was a retrospective cohort study using the United Network for Organ Sharing database. Recipient, donor, and center characteristics associated with induction use and early maintenance IS regimen were described. Multivariable Cox proportional hazards analysis evaluated induction receipt as a predictor of post-reLT survival.

RESULTS

There were 3483 adult reLT recipients from 2002 to 2018 at 116 centers with 95.6% being performed at the same center as the initial liver transplant. Timing of reLT was associated with induction IS use and the discharge regimen (P < 0.001 for both) but not with regimens at 6- and 12-month post-reLT (P = 0.1 for both). Among late reLTs (>365 d), initial liver disease cause was a more important determinant of maintenance regimen than graft failure cause. Low-reLT volume centers used induction more often for late reLTs (41.1% versus 22.6% high volume; P = 0.002) yet were less likely to wean to calcineurin inhibitors alone in the first year (19.1% versus 38.7% high volume; P = 0.002). Accounting for recipient and donor factors, depleting induction marginally improved post-reLT mortality (adjusted hazard ratio, 0.77; 95% CI, 0.61-0.99; P = 0.08), whereas nondepleting induction had no significant effect.

CONCLUSIONS

Although several recipient attributes inform early IS decision-making, this does not occur in a uniform manner and center factors also play a role. Further studies are needed to assess the effect of early IS on post-reLT outcomes.

摘要

背景

肝移植后(reLT)的首选免疫抑制(IS)策略尚未达成统一共识。

方法

这是一项使用 United Network for Organ Sharing 数据库的回顾性队列研究。描述了与诱导使用和早期维持 IS 方案相关的受者、供者和中心特征。多变量 Cox 比例风险分析评估了诱导接受作为 reLT 后生存的预测因素。

结果

2002 年至 2018 年,在 116 个中心进行了 3483 例成人 reLT 受者,其中 95.6%在与初始肝移植相同的中心进行。reLT 的时机与诱导 IS 的使用和出院方案相关(均 P < 0.001),但与 reLT 后 6 个月和 12 个月的方案无关(均 P = 0.1)。在晚期 reLT(>365 d)中,初始肝病的病因比移植物衰竭的病因更能决定维持方案。低 reLT 量中心更常为晚期 reLT 使用诱导(41.1%与高容量的 22.6%;P = 0.002),但在第一年更不可能单独转为钙调神经磷酸酶抑制剂(19.1%与高容量的 38.7%;P = 0.002)。在考虑受者和供者因素后,耗竭诱导剂可轻微改善 reLT 后的死亡率(调整后的危险比,0.77;95%CI,0.61-0.99;P = 0.08),而非耗竭诱导剂则无显著效果。

结论

尽管有几个受者特征可以帮助确定早期 IS 决策,但这种决策方式并不统一,中心因素也发挥了作用。需要进一步研究来评估早期 IS 对 reLT 后结果的影响。